


Salazopyrin ad infinitum!



“It is concluded that maintenance treatment of ulcerative colitis with sulphasalazine (salazopyrin) should be continued indefinitely unless contraindicated by side effects.”¹

The results of the above controlled trial carried out at the Nuffield Department of Clinical Medicine, Radcliffe Infirmary, Oxford are all the more welcome as earlier trials of cortisone² and prednisone³ at standard dosages have shown them to be ineffective in reducing the number of recurrences of ulcerative colitis.


“Fortunately, Sulphasalazine tablets, 0.5 grams 4 times a day will prevent relapses in the majority

of patients with colitis, and only a few patients cannot tolerate this relatively small dose, which can be continued indefinitely since we do not know when, if ever, it can be safely stopped”.⁴

Salazopyrin (sulphasazine) is available as the plain 0.5g. tablet, 0.5g. EN-tab and as an 0.5g. suppository.

Literature and detailed information on Salazopyrin are available on request.

“The patients who received dummy tablets had more than four times the relapse rate of those receiving sulphasalazine”.¹ (Salazopyrin).



Both groups of patients had been satisfactorily maintained for 1-5 years on Salazopyrin prior to the study, in which they took Salazopyrin or placebo for 6 months.

1. Gut (1973) 14 923-926
2. Brit. med. J. (1959) 1 387-394
3. Lancet (1965) i 188-189
4. General Practitioner (1972) April 7 p 11

Salazopyrin is a registered trade mark.

Further information on request from:-
Pharmacia (Great Britain) Ltd.
Paramount House,
75 Uxbridge Road,
London W5 5SS.
Telephone: 01-579 0102/7



Digestion

International Journal of Gastroenterology

Contents Vol. 13, No. 6, 1975

Original Papers

<i>Böhmer, R. and Rommel, K. (Ulm): Effect of Secretin on Intestinal Mono-saccharide Absorption and Net Water Movement in the Rat...</i>	325
<i>Balanzo, J. T. and Glass, G. B. J. (New York, N.Y.): Bioassay of Inhibitory Activity of Gastrone on Basal HCl Secretion in Rats with Chronic Gastric Fistula.....</i>	334

Recent Advances

<i>Douglas, A. P. and Weetman, A. P. (Newcastle upon Tyne): Lymphocytes and the Gut.....</i>	344
--	-----

Short Communications

<i>Pointner, H. (Vienna): Normal Serum Gastrin Levels in Patients with Liver Cirrhosis.....</i>	372
Obituary. Claude V. Perrier.....	375
Author Index.....	376
Subject Index.....	380
Contents Vol. 13.....	after 386



S. Karger
 Basel · München
 Paris · London
 New York · Sydney

Please complete the attached order form and return it to:
 S. Karger AG, Arnold-Böcklin-Strasse 25,
 CH-4011 Basel (Switzerland)

- Please enter my subscription
- Please send me a specimen copy

Name _____

Address _____




VIVONEX STIMULATED
for the high quality nutritional peak level

Vivonex HN

for restoring nitrogen balance in catabolic patients

Amino acids 17.7%, glucose solids 79.1%,
essential fat, vitamins and minerals; powder.
1.26 MJ/80 g.



Nature nearly discovered a cure for duodenal and gastric ulcers.



ASTRAGALUS
GLYCYPHYLLOS

We just perfected it.

For thousands of years, liquorice has been used medicinally. For the past thirty years, its efficacy in promoting the natural healing of gastric and duodenal ulcers has been acknowledged.

Now CAVED[®]-S offers the full therapeutic benefits of liquorice without the disadvantages which formerly limited its use. An exclusive process removes the glycyrrhizinic acid responsible for salt and water retention, without diminishing the efficacy of medicinal liquorice in accelerating ulcer healing.

With its proven record of reliability and lack of side effects, it makes sense to try CAVED[®]-S first when treating even the most severe ulcer cases.


CAVED[®]-S

It's naturally the treatment of choice.

Detailed information is available on request. [®]trademark.

Tillotts Laboratories Unit 24, Henlow Trading Estate,
Henlow, Beds. Telephone: 0462 813933

“...its prophylactic use may be confidently expected to reduce anaerobic sepsis rates of around 20 per cent and 50 per cent respectively to nil.”¹



It's not only in the prevention^{2,3,5,8,14,15,17} of anaerobic infections that 'Flagyl' has shown striking success; 'Flagyl' is also regarded as the agent of choice in the treatment of anaerobic infections.^{2-13,16}

The importance of 'Flagyl'* in this new indication is already firmly established. Both tablets and suppositories are available, to provide appropriate medication, in adults or children, in therapeutic and prophylactic applications.

Full prescribing information on request

*trade mark

References

- 1 *Scot. Med. J.*, **22**, 155, 1977
- 2 *Lancet*, **ii**, 1540, 1974
- 3 *Antimicrob. Agents & Chemother.*, **7**, 672, 1975
- 4 *J. Antimicrob. Chemother.*, **1**, 235, 1975
- 5 *Ibid.*, **i**, 393, 1975
- 6 *Br. Med. J.*, **i**, 39, 1975
- 7 *Nouv. Presse Med.*, **4**, 667, 1975
- 8 *Br. Med. J.*, **i**, 318, 1976
- 9 *J. Antimicrob. Chemother.*, **2**, 101, 1976
- 10 *Br. Med. J.*, **i**, 1074, 1976
- 11 *Lancet*, **ii**, 70, 1976
- 12 *Am. J. Obstet. Gynaecol.*, **126**, 1, 1976
- 13 *Br. Med. J.*, **ii**, 1418, 1973
- 14 *Lancet*, **ii**, 997, 1975

15 Willis, A. T., et al. *Br. Med. J.*, **607**, 1977

16 *J. Am. Med. Ass.*, **230**, 1168, 1974

17 *Lancet*, **ii**, 4, 1977

Product Licence Nos.

Tablets

200 mg 0012/5256

400 mg 0012/0084

Suppositories

500 mg 0012/0113

1 g 0012/0114

'Flagyl' is a trade mark of
May & Baker Ltd
Dagenham Essex RM10 7XS

 **M&B** May & Baker

A member of the Rhône-Poulenc
Group of Companies



MA5512



The Perfect Imitation

Vamin

The amino acid solution closely resembling W.H.O. egg protein standard.

The complete amino acid solution containing all 18 essential and non-essential L-form amino acids.

Intralipid

The isotonic fat emulsion derived from soya beans.


The most concentrated, safe, source of energy available for nutrition.

Simultaneous infusion of Intralipid and Vamin is the complete way to fulfil metabolic needs, maintain positive nitrogen balance and establish a good nutritional state.

KabiVitrum 

KabiVitrum Ltd., Bilton House,
Uxbridge Road, Ealing, London W5 2TH. Telephone 01-567 4717.
Full prescribing information available on request.

INTRALIPID
VAMIN



When dyspepsia repeats....

Maxolon

Unlike the traditional antacid therapies, Maxolon protects the gastric mucosa from over-long exposure to gastric acid¹ by promoting normal peristalsis and gastric emptying^{2,3}. By restoring the stomach's normal control, symptoms described by the patient as fullness, pain, heartburn and discomfort can be effectively treated and their recurrence prevented.⁴

To the patient, Maxolon is the simple and convenient therapy to replace his repetitive antacid prescriptions.


1 Gut, (1969), 10, 678-680. 2 Postgrad med J., (1973), 49, (Suppl), 29.
3 Gut, (1974), 15, 462-467. 4 Brit med J., (1971), 2, 25.



Full prescribing information is available on request.
Maxolon* (metoclopramide) is a product of

Beecham Research Laboratories, Brentford, England.

*regd.



Why Nalcrom should change your thinking about ulcerative colitis.

Prescribing Information

PRESENTATION: Nalcrom is a presentation of sodium cromoglycate for oral use. It is presented in clear, clear, hard gelatine capsules (printed Frisons 10) in black. Each capsule contains 100mg sodium cromoglycate as a white powder.

USES: As an adjuvant in the treatment of ulcerative colitis, proctitis and proctocolitis. Sodium cromoglycate is considered to exert a stabilising effect upon mast cells capable of releasing mediators, thus preventing the local inflammatory reaction in the gastrointestinal tract.

DOSAGE AND ADMINISTRATION: Dosage Adults: Two capsules four times daily.

Children: From 2-14 years, one capsule four times daily.

Nalcrom should not be used for children under two years.

Maintenance dosage: To prevent relapses dosage should be maintained indefinitely at two capsules four times daily in adults and one capsule four times daily in children.


Administration: The capsules may be swallowed whole or alternatively the powder contents may be dissolved in 20-30ml of water and swallowed.

Nalcrom offers a completely new approach to the management of ulcerative colitis.

And it could mean freedom from side effects often associated with the limited number of treatments now available.

Nalcrom is sodium cromoglycate.


Sodium cromoglycate is the unique drug which is used successfully in the treatment of allergic diseases, such as asthma and rhinitis.



Sodium cromoglycate prevents the degranulation of mast cells caused by the interaction of antigens and reagin antibodies.

It is a potent inhibitor of mast cell degranulation. It prevents the release of inflammatory agents into sub-mucosal tissue in the lung, nose and other organs. So it stops symptoms before they start. And over ten years of clinical use it has proved it to be a very effective drug with remarkably few serious side-effects.


Now it offers hope as a new treatment for ulcerative colitis.



On left mast cell undergoing gross degranulation. On right mast cell stabilised after treatment with sodium cromoglycate. Photomicrographs prepared by: R & D Laboratories, Fisons Ltd., Pharmaceutical Division.

Why an anti-allergy drug?

Ulcerative colitis in its natural history and histological appearance has many features such as macrophages, mast cells and eosinophils that suggest that an allergic or immunological process may be involved. Sodium cromoglycate may have a clinically beneficial effect in these processes. So a double blind cross-over trial was carried out with 26 patients suffering from chronic proctitis¹. The 14 responders to sodium cromoglycate had a high local eosinophil count which in most cases fell in the course of treatment.



In a double-blind cross-over trial of 26 patients, 14 responded to sodium cromoglycate, 10 didn't respond and 2 responded to placebo.

Another study of 12 patients with ulcerative colitis treated with sodium cromoglycate showed a significant improvement in sigmoidoscopic appearance. And again, rectal biopsies showed a significant reduction in eosinophil counts^{2,3}.

How to find out more about Nalcrom.

Specialist representatives are available at this stage to discuss Nalcrom with hospital doctors. Simply fill in and post the coupon or write to: Fisons Limited, Pharmaceutical Division, Loughborough, Leicestershire.

Nalcrom[®]
(Sodium Cromoglycate B.P.)

References 1. Heatley, R.V. et al. 1975, "Gut," **16**, 559 2. Mani, V. et al. 1976, "Lancet," **1**, 439 3. Mani, V. et al. 1977, "Gastro-enterology," **72**, 1093

Please arrange for a specialist representative to call.

Name _____

Address _____

Further information is available on request from Fisons Limited, Pharmaceutical Division, Loughborough, Leicestershire.

FISONS[®]
Leaders in Allergy Research

CONTRA-INDICATIONS, WARNINGS, ETC. Contra-indications There are no specific contra-indications. The safety of Nalcrom during pregnancy has not yet been established.

Side-effects Nausea has been reported in a few cases.

Overdosage As Nalcrom is absorbed only to a very limited extent, no action other than medical observation should be necessary.

PHARMACEUTICAL PRECAUTIONS: Store in a dry place. Reclose the container tightly after use.

LEGAL CATEGORY: P.O.M.

PACKAGE QUANTITIES: Containers of 100 capsules.

FURTHER INFORMATION: 1. Nalcrom may be used in conjunction with steroid therapy and sulphasalazine in the treatment of acute relapses of proctocolitis and in maintaining remissions.

2. If steroid therapy is to be reduced or withdrawn this should be done cautiously.

3. Nalcrom may be used in patients with a history of hypersensitivity to or intolerance of sulphasalazine.

4. Dosages of 2000mg daily have been used in some cases of proctocolitis.

PRODUCT LICENCE NUMBER: PL 0113/0073.

An important new book from Churchill Livingstone

Essentials of Paediatric Gastroenterology

Edited by **J. T. Harries**

384 pages illustrated £11.00

The purpose of this volume is to cover the important areas of a rapidly growing speciality, paediatric gastroenterology.

The book is arranged in three parts. The first deals with the prenatal development of structure and function with particular emphasis on the small gut, and an account of the currently available investigatory techniques.

The second part of the book considers a variety of conditions but, in the main, is orientated towards the alimentary tract.

The third part is devoted to disorders of the liver and pancreas in childhood.

Extensive bibliographies have been included in selected parts of the book, providing an opportunity for readers to pursue certain subjects in depth.

23 Ravelston Terrace
Edinburgh EH4 3TL



Churchill Livingstone

Disorders of Lipid Metabolism

The Proceedings of a Symposium organized by the Association of Clinical Pathologists

CONTENTS: Cholesterol metabolism ● Plasma triglyceride metabolism ● Phospholipids and their metabolism ● Lipid methodology ● Diet and triglyceride metabolism ● Classification of lipoproteins and lipoprotein disorders ● Lipoprotein fractionation ● The pathogenesis of atherosclerosis ● Plasma lipids and atherosclerosis ● Evidence for a defect in fatty acid uptake by adipose tissue of patients with hypertriglyceridaemia ● Hypolipoproteinaemia ● The enterohepatic circulation of bile acids as they relate to lipid disorders ● Secondary hyperlipidaemia ● Therapy of lipid disorders.

PRICE: Inland £2.00; Abroad US \$5.00 including postage


Payment must be enclosed with order or surcharge of 30p will be made for rendering invoices and statements

This publication can be ordered *now* from: The Publishing Manager

JOURNAL OF CLINICAL PATHOLOGY

B.M.A. House, Tavistock Square, London WC1H 9JR

"No Sweat"



NEW microporous adhesive seal

Washer Pressure plate

Tip in Karava seal

Laminated tear-resistant plastic


Another Hollister advance in post-operative ostomy care. New microporous seal to let the skin 'breathe'!

The new Hollister® post-operative ostomy bag retains all the proven features which make our standard bags so popular. The innovation is a revolutionary new resilient, microporous seal which allows the skin to 'breathe', and minimises tugging and skin abrasion. With conventional plastic-backed seals, the accumulation of perspiration causes skin soreness, and increases adhesion problems.

With the new Hollister microporous adhesive, air can circulate through a network of pores, evaporating perspiration, and keeping the skin beneath the seal dry and comfortable. The seal integrity is maintained, and leakage and skin sensitivity problems are minimised.

Best part of all is the price - exactly the same as for our other drainable bags.

If you think our new bags couldn't possibly be better than our standard type - just send for a sample, try it on a patient, and then ask him.



Would like more information about your new creation? Must ask for it in a letter to:

Name _____

Title _____

Address _____

Hollister Products Laboratories, Inc.
 Ostomy Products Division - Freeport
 200 East Main Street, Waukegan, Ill. 60087

NO STAMP
 REQUIRED

A product of **HOLLISTER** **ABBOTT**

TRADE MARK OF HOLLISTER INCORPORATED CHICAGO ILLINOIS 60602

HE 925



DOROTHY'S REFINED HABITS HAVE LED TO A SERIOUS PROBLEM.

Many patients suffer from serious conditions such as haemorrhoids, diverticular disease, irritable colon or anal fissure, which may be associated with long standing dietary constipation.

These problems won't be resolved overnight. Fybogel, by quickly restoring natural fibre to the diet, relieves the constipation and rapidly improves the symptoms of the condition.



Fybogel sachets contain 3.5 g Ispaghula husk BPC
Full prescribing information is available on request from
Reckitt & Colman Pharmaceutical Division, Hull HUB 7DS.
Fybogel is a registered trademark. PL No. 0044/0041. 1127



the natural way to end dietary constipation



Reduces gastric acid secretion.

New data now available.

1 Healing

Further experience in clinical trials confirms that 4-8 weeks 'Tagamet' treatment achieves remarkable results in duodenal ulcer,^{1,2,3} gastric ulcer,^{2,4,6} and reflux oesophagitis.^{2,5}

Overall Experience	TAGAMET % healed	PLACEBO % healed
Duodenal Ulcer	77% of 803 patients	41% of 252 patients
Gastric Ulcer	79% of 130 patients	45% of 64 patients
Reflux Oesophagitis*	62% of 39 patients	9% of 23 patients

*includes oesophageal ulcers and erosions: complete healing or marked improvement.

In addition to complete healing (proven endoscopically), early and dramatic symptomatic relief is achieved in most patients. With its convenient dosage and low incidence of side effects, 'Tagamet' is well suited to everyday treatment.

2 Recurrence

A group of duodenal ulcer patients was followed for periods of up to 6 months after completing 4-6 weeks 'Tagamet' treatment. Preliminary results show that the incidence of relapse was no greater than in a similar group who had healed their ulcers on placebo.^{2,7}



Artist's impression of H₂ receptor antagonist acting at receptor site in gastric mucosa.

3 Maintenance

377 chronic duodenal ulcer patients, who had healed their ulcers after 4-6 weeks treatment were entered into controlled, double-blind maintenance trials. They were maintained on 'Tagamet' or placebo therapy, at a reduced dosage, for periods of up to 6 months. Results from these ongoing studies have shown that only 5.7% of the 'Tagamet' group relapsed⁷ compared with 42.1% of the group who were maintained on placebo.



References

1. Oral cimetidine in severe duodenal ulceration, (1977) *Lancet*, i, 4.
2. Data on file (March 1977), Smith Kline & French.
3. The effect of cimetidine on duodenal ulceration (1977). The Second International Symposium on Histamine H₂ Receptor Antagonists. Excerpta Medica, p.260.
4. Treatment of gastric ulcer by cimetidine. (1977) *ibid.* p.287.
5. Cimetidine in the treatment of oesophagitis. (1977) *ibid.* p.297.
6. Healing of gastric ulcer during treatment with cimetidine. (1976) *Lancet*, i, 337.
7. Long-term treatment with cimetidine in duodenal ulceration (1977) *Lancet*, i, 900.

'Tagamet' (cimetidine) is available as 200mg film-coated tablets, 200mg/5ml syrup and 200mg/2ml ampoules.

Full prescribing information is available from Smith Kline & French Laboratories Limited, a Smith Kline company, Welwyn Garden City, Hertfordshire, AL7 1EY. 'Tagamet' is a trade mark.

Tagamet

(cimetidine, SK&F)



The H₂ receptor antagonist
Reduces gastric acid secretion


SK&F

TG AD 167

New from
SQUIBB SURGICARE LIMITED

Colostomy Pack

incorporating
the **New** Colostomy Pouch Mk. 1
with Stomahesive and Flange



+ Special Sealing Ring

The Squibb Surgicare Colostomy Pack:
a new, easy-to-use system of colostomy management
ensuring freedom from skin problems with extra
security comfort and convenience

From the inventors of Stomahesive™

Further information is available on request from
SQUIBB SURGICARE LIMITED
Regal House Twickenham TW1 3QT

Stomahesive is the registered trade mark of E. R. Squibb and Sons Limited

Published September 1977

Hypoxia and Ischaemia

*The Proceedings of a Symposium organized by the
Royal College of Pathologists*

Edited by Basil C. Morson

Factors influencing oxygen availability	I. MCA. LEDINGHAM
Local factors in tissue oxygenation	I. A. SILVER
The biochemical consequences of hypoxia	K. G. M. M. ALBERTI
Hypoxia and the pulmonary circulation	DONALD HEATH
Hypoxia and the carotid body	J. M. KAY AND P. LAIDLER
The pathology of myocardial ischaemia	M. J. DAVIES
Animal models of myocardial ischaemia	N. WOOLF
Responses of the splanchnic circulation to ischaemia	ADRIAN MARSTON
Ischaemic bowel disease	T. ALSCHIBAJA AND B. C. MORSON
Ischaemia of bone	MARY CATTO
Ischaemia of peripheral nerve and muscle	D. G. F. HARRIMAN
Hypoxia and tumours	R. H. THOMLINSON
The pathology of renal ischaemia	J. R. TIGHE
Renal necrosis	J. F. SMITH
The effects of hypoxaemia in fetal sheep	J. S. ROBINSON, C. T. JONES, AND G. D. THORBURN
Hypoxia in the newborn infant	E. O. R. REYNOLDS
Pathology of perinatal hypoxia	ALBERT E. CLAIREAUX
The concepts of thresholds of ischaemia in relation to brain structure and function	LINDSAY SYMON, N. M. BRANSTON, A. J. STRONG, AND T. D. HOPE
Structural abnormalities in neurones	A. W. BROWN
Pathology of hypoxic brain damage in man	D. I. GRAHAM
Experimental hypoxic brain damage	J. B. BRIERLEY

PRICE: Inland £5.00; Abroad US \$10.00 including postage

Payment must be enclosed with order or surcharge of 30p will be made for rendering invoices and statements

This publication can be ordered now from

The Publishing Manager, JOURNAL OF CLINICAL PATHOLOGY
B.M.A. House, Tavistock Square, London WC1H 9JR